PCSA - Processa Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.5000
0.0000 (0.00%)
At close: 3:38PM EDT
Stock chart is not supported by your current browser
Previous Close2.5000
Open2.0200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.5000 - 2.5000
52 Week Range1.5000 - 4.2000
Volume1,400
Avg. Volume498
Market Cap97.002M
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that they have signed an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. HT-100 is an orally available anti-fibrotic, anti-inflammatory drug that also promotes healthy muscle fiber regeneration.  In previous clinical trials in Duchenne Muscular Dystrophy (DMD), HT-100 showed promising improvement in the muscle strength of non-ambulant pediatric patients.  Although FDA placed a clinical hold on the DMD trial after a serious adverse event in a pediatric patient, FDA has removed the drug off of clinical hold and defined how HT can resume clinical trials in DMD.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the last patient has been enrolled in the Phase 2 Necrobiosis Lipoidica (NL) clinical trial for PCS-499. Completing the enrollment of the last patient in this clinical trial represents a significant clinical development milestone for PCS-499 and moves us a step closer to potentially bringing this new treatment forward to help patients suffering from NL.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update for its on-going Phase 2 Necrobiosis Lipoidica (NL) clinical trial for PCS-499 (PCS499-NL01), a deuterated analog of one of the major metabolites of pentoxifylline (Trental®). Although the main objective of the trial is to evaluate the safety and tolerability of PCS-499 in patients with NL, safety and efficacy data collected from this trial is expected to provide information for the design of future clinical trials. Based on toxicology studies and healthy human volunteer studies, Processa and the FDA agreed that a PCS-499 dose of 1.8 grams/day would be the highest dose administered to NL patients in this Phase 2 trial.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be presenting at the Jeffries Conference on Friday, June 7th at 8:30 AM. Dr. David Young (Chief Executive Officer) and Patrick Lin (Chief Business and Strategy Officer) of Processa Pharmaceuticals will be giving the presentation and are available to meet with investors. The Jeffries 2019 Global Healthcare Conference will be held at the Grand Hyatt in New York City.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be presenting at the Cowen Conference on Wednesday, March 13 at 9:20 AM followed by a breakout session at 10:00 AM. Dr. David Young (Chief Executive Officer) and Patrick Lin (Chief Business and Strategy Officer) of Processa Pharmaceuticals will be giving the presentation and are available to meet with investors. The 39th Annual Healthcare Conference will be held at the Marriott Copley in Boston, Massachusetts, For more information or to schedule a one-on-one meeting with the Company, please contact Patrick Lin at plin@processapharma.com or call 925.683.3218.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the dosing of the first patient in the Phase 2 Necrobiosis Lipoidica (NL) clinical trial for PCS-499—which is taking place at 2 sites: University of Pennsylvania and University of Pittsburgh Medical Center (UPMC). Misha Rosenbach, M.D. is the Principal Investigator and an Associate Professor of Dermatology in the Perelman School of Medicine at the University of Pennsylvania. Dr. Rosenbach stated “Necrobiosis Lipoidica is an incredibly rare and often devastating disease for patients, and there is a need for high quality, evidence-based medicine to help guide therapeutic decision making.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that the American Academy of Dermatology (AAD) has selected the Processa presentation on the “Study Design and Preliminary Safety and Tolerability of PCS499 for Treatment of Necrobiosis Lipoidica (NL)” for an oral presentation and ePoster at the 2019 Annual Meeting of Washington, DC, March 1-5, 2019. The presentation will be delivered by Dr. Maya Das, VP of Clinical Research at Processa. “Although constrained by dose limiting side effects, the off-label success of pentoxifylline (PTX) in a small number of NL patients has demonstrated that a number of the pharmacological properties of PTX and its active metabolites could be beneficial in the treatment of NL.

  • GlobeNewswire

    PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET

    Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that its stock has commenced trading on the OTCQB Market (OTCQB) after successfully up-listing from the OTC Pink Market. The Company believes its listing on the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the U.S. Securities and Exchange Commission (SEC) as an "established public market" for the purpose of determining the public market price when registering securities for resale with the SEC.